-
Rosiglitazone in Beige-Fat Assay Design
2026-09-12
Rosiglitazone (Brl-49653) provides a mechanistic PPARγ control for studying adipocyte differentiation, insulin sensitivity, and thermogenic remodeling. This guide connects the compound to the SEMA3E–β-catenin findings while emphasizing assay design, interpretation, and evidence boundaries.
-
HOXC8, Caspase-1, and Pyroptosis in NSCLC
2026-09-11
The reference study identifies HOXC8 as a context-dependent oncogenic factor in non-small cell lung cancer (NSCLC) that prevents pyroptotic death by repressing CASP1 transcription through HDAC1/2 recruitment. Its findings connect transcriptional control of inflammatory caspase abundance with tumor-cell survival and suggest that disrupting the HOXC8–HDAC–CASP1 axis may provide a mechanistically distinct approach to studying lung tumorigenesis.
-
AI-10-49 Workflows for inv(16) AML Research
2026-09-11
AI-10-49 enables a mechanism-led workflow that connects CBFβ-SMMHC target engagement with RUNX1 chromatin recovery, leukemia cell proliferation inhibition, and downstream MYCN–eIF4G1 biology. This guide translates those findings into practical cell, chromatin, and in vivo leukemia mouse model experiments while addressing solubility, assay timing, and interpretation risks.
-
WP1066: JAK2/STAT3 Inhibitor Workflows
2026-09-10
WP1066 is a cell-permeable pathway probe for linking JAK2/STAT3 signaling to cancer-cell growth, apoptosis, and macrophage-state changes. This practical guide separates established oncology applications from emerging scaffold-based regeneration studies and provides concentration, timing, readout, and troubleshooting strategies.
-
ATRX Loss Sensitizes Glioma Cells to RTK Inhibitors
2026-09-10
The reference study identifies ATRX deficiency as a potential determinant of sensitivity to multi-targeted receptor tyrosine kinase and PDGFR inhibitors in high-grade glioma cells. Its combination data with temozolomide support incorporating ATRX status into preclinical design and interpretation of targeted-therapy studies, while underscoring the need to validate these findings beyond cell-based models.
-
Metformin Hydrochloride: From Metabolism to Tendon HO
2026-09-09
Metformin Hydrochloride is more than a glucose-metabolism tool: it enables mechanism-aware studies of AMPK, redox control, and tendon heterotopic ossification. This article translates recent Nr4a1/Wnt/β-catenin findings into practical assay-design decisions.
-
MK-5108 (VX-689) Aurora A Assays
2026-09-09
MK-5108, also known as VX-689, enables selective Aurora A interrogation in biochemical, cell-based, and tumor-model workflows. This guide translates retinoblastoma findings into practical assay design, dose selection, controls, and troubleshooting strategies while distinguishing research evidence from experimental recommendations.
-
HyperScribe™ T7 High Yield RNA Kit for ac4C
2026-09-08
The HyperScribe T7 High Yield RNA Synthesis Kit enables controlled RNA production for ac4C-focused assay design, including capped RNA synthesis and biotinylated RNA synthesis. This article explains how to translate NAT10–ac4C findings in mouse oocytes into better controls, probe strategies, and interpretation of in vitro transcription experiments.
-
Polybrene Workflow Guide for Viral Transduction
2026-09-08
Build more reproducible lentiviral, retroviral, and lipid-mediated DNA delivery workflows with Polybrene while controlling exposure-related cytotoxicity. This guide also explains how delivery optimization can support engineered-cell assays inspired by emerging FBXO22 targeted protein degradation research.
-
WY-14643: PPARα Signaling Beyond Lipid Control
2026-09-07
Explore how WY-14643 (Pirinixic Acid) links PPARα-driven metabolic regulation with YAP-TEAD-dependent liver remodeling, and how translational teams can validate this biology.
-
U0126: MEK1/2 Inhibition in MAPK/ERK Research
2026-09-05
U0126 is a cell-permeable, non-ATP-competitive MEK1/2 inhibitor that suppresses ERK1/2 phosphorylation. Its defined kinase potency and formulation properties support mechanistic studies of MAPK/ERK signaling, cancer biology research, neurobiology, autophagy, and mitophagy.
-
Se-methylselenocysteine Rewires NRF2 Stress in PDAC
2026-09-05
A 2026 study shows that se-methylselenocysteine engages KYAT1-dependent NRF2 and ATF4 stress programs in pancreatic ductal adenocarcinoma, but with strongly phenotype-specific transcriptional and ferroptosis-associated outcomes. Its findings connect redox adaptation, lipid peroxidation, iron handling, and metabolic heterogeneity, providing a framework for testing oxidative stress modulation and pathway dependence in pancreatic cancer models.
-
Removing Pollen Interference in Bioaerosol EEM
2026-09-04
The reference study shows that pollen can distort excitation–emission matrix fluorescence spectroscopy used to classify hazardous bioaerosols. Combining spectral preprocessing, fast Fourier transform feature conversion, and random forest classification improved recognition to 89.24%, offering a practical strategy for more reliable environmental screening.
-
Glioblastoma Vulnerability to BH3-Mimetic Therapy
2026-09-04
The reference study shows that glioblastoma, including stem-like tumor cells, is unusually dependent on the anti-apoptotic proteins BCL-XL and MCL-1. Its combination of expression profiling, functional dependency testing, and xenograft experiments supports sequential BCL-XL/MCL-1 targeting as a preclinical strategy for exploiting apoptotic priming.
-
GKT137831: Dual Nox1/Nox4 Inhibitor Workflow
2026-09-03
GKT137831 enables controlled interrogation of Nox1/Nox4-driven oxidative signaling in pulmonary vascular, hepatic, cardiovascular, and metabolic models. This practical guide connects dose selection, ROS assays, membrane-injury readouts, and troubleshooting to help distinguish upstream redox control from downstream ferroptotic execution.